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Editorial on the Research Topic
Radioimmunotherapy—Translational Opportunities and Challenges
It has become evident that radiotherapy has both, immune suppressive, and immune activating
properties (1). This is why this important component of cancer treatment should be combined
with immune therapies to shift the balance toward immune activation against tumor cells.
During the last decade a manifold of pre-clinical work was put into investigation of combination
of radiotherapy either with additional immune stimulants such as cytokines or vaccines or
in combination with antibodies that target immune suppressive molecules such as immune
checkpoint inhibitors. Luckily, some of these approaches are currently tested in clinical trials, high
lightening the huge translational opportunities by examination of modes of action of radiotherapy
in combination with immunotherapy; named in this special issue radioimmunotherapy. However,
one has always to keep in mind that many challenges do still exist such as what is the best sequence
and timing of joint applications, what are the best immunotherapy approaches, how to overcome
tumor resistances, what about healthy tissue cytotoxicity, or which biomarkers or matrices of
biomarkers are most beneficial for patients stratification, just to mention the most burning ones.
The articles in this special issue grab many of these challenges.
Integration of radiotherapy in multimodal tumor treatments is not to be challenged since
above half of the tumor patients do receive it during their diseases history. Further, it has
been proven that locally applied radiotherapy does not destroy the immune system in a way
that additional immunotherapy is not feasible. Voos et al. show that exposing cells of the
adaptive immune system, namely T cells, to radiation even results in their Ca2+-dependent
activation. Furthermore, radiation-exposed T cells adhered better to endothelial cells (Voos
et al.). Nevertheless, these features might impact both, toxic effects of radiation and a better T
cell-mediated treatment response. The latter can be enhanced by immune activatory cytokines.
This is the focus of the work of Palata et al. who review on the efficacy of combination
treatments of radiotherapy with IL-2, IFN-alpha, TNF-alpha, GM-CSF, and immunocytokine-
based approaches which are already tested in clinical trials. Additionally, work about IL-12
and IL-15-based immunotherapy approaches is presented. This again high lights the huge
translational opportunities of radioimmunotherapies (Palata et al.). Besides cytokines, active
stimulation of the immune system can be achieved by vaccination approaches. Seitz et al.
demonstrate for the first time in pre-clinical model systems that radiotherapy can be combined
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with vaccination with syngeneic whole-tumor cell vaccine
generated by high hydrostatic pressure, mimicking in cancer
patients autologous vaccine from their own tumor cells.
Radiotherapy thereby acts as an adjuvant for the vaccine
that contains many tumor-associated antigens (adjuvanticity
plus antigenicity) (Seitz et al.). The work of Liu et al. gives
some additional hints that whole-body irradiation with low
doses enhances the in situ vaccine effects of locally applied
radiotherapy. This reflects the complexity and diversity of
mechanisms of radiation-induced immune modulation. While
low radiation doses mostly seem to enhance immune cell
infiltration into tumors, higher doses do induce immunogenic
cancer cell death, and create an immune stimulatory micro-
environment for the attracted immune cells.
The change in the stromal compartments of tumors following
radiation exposure have to be followed very detailed for
future radioimmunotherapy optimization. Martinez-Zubiaurre
et al. particularly summarize the time-dependence of stromal
changes following radiation exposure. Only short windows
of opportunities might exist for effective combination of
radiotherapy with immune therapies (Martinez-Zubiaurre
et al.). Sevenich summarizes the key features how to turn
immunological “cold” into “hot” tumors and discusses an
additional challenging fact about immune properties of
different tumor entities. Particularly brain tumors have
highly immune suppressive properties and are located at an
immune privileged site. Nevertheless, immune cells do infiltrate
brain tumors and distinct well-elaborated combinations of
radiotherapy with immune therapy could be successful for
primary and metastatic brain tumors (Sevenich). Buchwald
et al. review about pre-clinical and clinical work dealing with
radioimmunotherapy-induced immune responses against the
primary, irradiated, and abscopal, non-irradiated, tumor masses.
They stress that besides the tumor location, timing, dose, and
fractionation strongly impacts anti-tumor immune responses.
They focus on T cell exhaustion and on how radiotherapy
should be combined with immune checkpoint-inhibitors
such as antibodies targeting the PD-1/PD-L1 network in
this context (Buchwald et al.). One has never to forget that
classical tumor features such as hypoxic regions have to be
taken into account, as these regions do also show immune
suppressive features such as increased amounts of regulatory
T cells and myeloid-derived suppressor cells and increased
concentrations of TGF-beta. Eckert et al. stress that particularly
patients with hypoxic tumors might therefore benefit from
radioimmunotherapies.
Since multiple immune suppressive properties of tumors
do exist, combined approaches that aim to both, activate
tumor-reactive T cells, and neutralize exhausted T cells should be
more efficient. Ostrand-Rosenberg et al. report about bispecific T
cell engagers (BiTE) that activate and target cytotoxic T cells and
natural killer T cells to kill PD-L1 expressing tumor cells. They
further stress that additional combination with co-stimulatory
sCD80 increases T cell-mediated anti-tumor immune responses
and should be tested in the future in combination with
radiotherapy (Ostrand-Rosenberg et al.). Another innovative
approach of targeted stimulation of anti-tumor immune
responses is the use of functionalized superparamagnetic iron
oxide nanoparticles (SPIONs), as outlined by Janko et al. These
nanoparticles have the great advantage to locally targeting the
tumor by reducing side effects. Besides cytotoxic agents, immune
modulatory molecules can be coupled to these particles and by
application of an external mantic field, additional heating of the
tumor is possible, again contributing to enhanced immunogenic
features of the tumor (Janko et al.).
In all of the described approaches of combining radiotherapy
with immune modulators, patient’s stratification is of key
importance. Here, immune contextures play a central role,
besides genetic features of the tumor (e.g., tumor mutational
burden) and viral pathogenic factors, since the latter seem to
impact radiation sensitivity and antitumor immunity (2). Clinical
data about association of viral polyomavirus load and CD8+
T cell infiltration into Merkel cell carcinoma are presented by
von der Grün et al. While high viral load was associated with
worse overall survival (OS), high intratumoral CD8+ T cell
was associated with improved OS. Importantly, expression of
immune suppressive PD-L1 was correlated with increased T cell
infiltration. These clinical observations once more stress that
multiple immune features do impact on efficient anti-tumor
immune responses.
Radiotherapy in this context has functions as immune
stimulator, immune suppressor, and as fine-tuner of
immune responses. Let’s go ahead with multimodal
radioimmunotherapies for cancer. The knowledge about
joint actions of radiotherapy and immunotherapy is increasing
daily and the results of the ongoing clinical trials will help to
further improve personalized radioimmunotherapies.
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